Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
ZNF146
REST API REST API
Homo sapiens
ZNF146 is differentially expressed in 275 experiments: 108 organism parts: liver, bone marrow, ... (106 more);, 186 disease states: normal, acute myeloid leukemia, ... (184 more);, 95 cell types 296 cell lines 41 compound treatments and 76 other conditions.
Synonyms OZF
Orthologs ENSCING00000009885 (Ciona intestinalis)   Zfp146 (Mus musculus)   Q4H2K7_CIOIN (Ciona intestinalis)   LOC687516 (Rattus norvegicus)   ZNF146 (Danio rerio)   (Compare orthologs)
InterPro Term Znf_C2H2-like, Znf_C2H2
Gene Ontology Term DNA binding, regulation of transcription, DNA-dependent, cytoplasm, intracellular, heparin binding, metal ion binding, nucleus, nucleolus, zinc ion binding
UniProt Accession Q15072
Search EB-eye ENSG00000167635
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-6573, E-GEOD-1577, E-GEOD-3526, E-MTAB-62, E-TABM-125, ... (25 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-GEOD-19639, E-GEOD-18005, E-GEOD-19397, ... (35 experiments)

Factor Value U/D Experiments
MCF-7
3
E-GEOD-19639, E-GEOD-3529, E-GEOD-20081
MDA468
2
E-MEXP-440, E-MTAB-62
SW480
2
E-MEXP-1014, E-GEOD-18005
NCIH1666
1
E-MTAB-37
C7H2-R3B5
1
E-GEOD-22152
Hep3B
1
E-MTAB-37
290 more value(s).


Cell type

studied in E-GEOD-16058, E-GEOD-22373, E-GEOD-21668, E-GEOD-3920, E-GEOD-20677, ... (44 experiments)

Factor Value U/D Experiments
CD14+ monocyte
2
E-AFMX-5, E-MEXP-1600
CD19+ B cells (neg. sel.)
2
E-AFMX-5, E-TABM-145
embryonic stem cell
2
E-MEXP-930, E-GEOD-26672
human embryonic stem cell
2
E-GEOD-20033, E-GEOD-18265
M1 macrophage
1
E-GEOD-5099
hematopoietic
1
E-GEOD-9894
89 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-GEOD-1577, E-TABM-15, ... (68 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
4
E-MTAB-62, E-GEOD-2514, E-MTAB-37, E-MEXP-231
prostate carcinoma
3
E-MTAB-62, E-MEXP-1327, E-GEOD-96
uterine fibroid
2
E-GEOD-7307, E-MTAB-62
adrenocortical carcinoma
2
E-TABM-311, E-GEOD-10927
glioblastoma
2
E-GEOD-4290, E-GEOD-6014
multiple myeloma
2
E-MTAB-62, E-GEOD-2113
180 more value(s).


Compound treatment

studied in E-GEOD-7400, E-GEOD-5258, E-TABM-782, E-GEOD-3720, E-GEOD-5824, ... (26 experiments)

Factor Value U/D Experiments
none
2
5
E-GEOD-5824, E-TABM-782, E-GEOD-412, E-GEOD-995, E-TABM-868, ... (7 experiments)
DMSO
1
E-MEXP-1561
sapphyrin PCI-2051
1
E-GEOD-6400
TNF
1
E-GEOD-15205
5-aza-2'-deoxycytidine
2
1
E-MEXP-1269
vitamin E
1
E-MEXP-1327
35 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
tunicamycin
1
E-GEOD-19519
DMSO
1
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519


Biosource provider
studied in E-TABM-325, E-MTAB-37

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cell treatment
studied in E-MEXP-1192

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-22097, E-GEOD-19743, E-GEOD-7967, E-GEOD-21589, E-GEOD-16363, ... (6 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-860, E-MEXP-1251, E-GEOD-2191, ... (7 experiments)

Clinical treatment
studied in E-GEOD-6532

Construct
studied in E-GEOD-22369, E-GEOD-22366

coriell cell line repository identifier
studied in E-GEOD-19519

development stage
studied in E-GEOD-22601

Developmental stage
studied in E-GEOD-1614, E-GEOD-16058, E-GEOD-20033, E-MEXP-2359, E-MTAB-62 ... (5 experiments)

dfs time (months)
studied in E-GEOD-21653

Disease staging
studied in E-GEOD-19743, E-TABM-147, E-GEOD-21138, E-GEOD-1751

double amplification
studied in E-GEOD-22601

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-4025, E-MEXP-1482, E-GEOD-20847, E-MTAB-108, E-GEOD-6431, ... (8 experiments)

Genotype
studied in E-GEOD-3494, E-GEOD-2466, E-GEOD-17476, E-TABM-321, E-GEOD-18736, ... (9 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-GEOD-5681, E-MEXP-1446, E-GEOD-22278, ... (10 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276, E-GEOD-20194, E-GEOD-16716 ... (5 experiments)

Individual
studied in E-TABM-325, E-GEOD-2466, E-GEOD-1926, E-MEXP-2069, E-MEXP-1648, ... (29 experiments)

Infection
studied in E-MEXP-1274, E-GEOD-980, E-GEOD-17400, E-GEOD-6802, E-GEOD-512 ... (5 experiments)

Injury
studied in E-GEOD-19743

Irradiate
studied in E-GEOD-1977, E-TABM-321

Karyotype
studied in E-GEOD-7214

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

Organism
studied in E-GEOD-7540, E-GEOD-426, E-TABM-84

Organism status
studied in E-GEOD-19188

Pcr vs rd
studied in E-GEOD-20194, E-GEOD-16716

Phenotype
studied in E-GEOD-19703, E-GEOD-22309, E-GEOD-21750, E-GEOD-1460

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246

pt
studied in E-GEOD-21653

Replicate
studied in E-TABM-585, E-GEOD-18791, E-GEOD-10896

RNAi
studied in E-GEOD-12438, E-MEXP-101, E-GEOD-3697, E-MEXP-1857, E-MEXP-1315 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-MEXP-70

Sex
studied in E-GEOD-19069, E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996, E-TABM-125

Survival time
studied in E-GEOD-3494, E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276, E-GEOD-2748

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-16837, E-GEOD-21909, E-GEOD-19246, ... (6 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-1561, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.309 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM